Sivia Capital Partners LLC Takes Position in Medpace Holdings, Inc. $MEDP

Sivia Capital Partners LLC purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 944 shares of the company’s stock, valued at approximately $296,000.

Several other institutional investors and hedge funds have also recently modified their holdings of MEDP. Mawer Investment Management Ltd. bought a new position in shares of Medpace during the first quarter valued at $212,131,000. Vulcan Value Partners LLC increased its holdings in Medpace by 221.6% in the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock worth $99,159,000 after buying an additional 224,578 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Medpace by 675.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock worth $37,009,000 after buying an additional 105,807 shares in the last quarter. Invesco Ltd. increased its holdings in Medpace by 9.4% in the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after buying an additional 102,015 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Medpace by 41,658.9% in the 1st quarter. GAMMA Investing LLC now owns 93,540 shares of the company’s stock worth $28,501,000 after buying an additional 93,316 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 0.8%

MEDP stock opened at $501.94 on Friday. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $506.55. The stock has a market cap of $14.10 billion, a P/E ratio of 37.32, a PEG ratio of 3.13 and a beta of 1.44. The business’s 50-day moving average price is $443.38 and its 200-day moving average price is $353.86.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million for the quarter, compared to analysts’ expectations of $537.70 million. During the same period in the previous year, the firm earned $2.75 EPS. The business’s quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Stephen P. Ewald sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total value of $1,350,000.00. Following the transaction, the general counsel directly owned 10,343 shares of the company’s stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin M. Brady sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $454.23, for a total value of $5,450,760.00. Following the completion of the transaction, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $2,725,380. This represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 161,266 shares of company stock worth $74,111,427 in the last quarter. 20.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on MEDP. Truist Financial lifted their price objective on Medpace from $298.00 to $436.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and lifted their price objective for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Robert W. Baird lifted their price objective on Medpace from $313.00 to $490.00 and gave the stock a “neutral” rating in a report on Wednesday, July 23rd. Rothschild Redb downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Finally, Mizuho lifted their price objective on Medpace from $328.00 to $510.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Medpace presently has an average rating of “Reduce” and an average price target of $422.27.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.